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Abstract
The purpose of this study was to evaluate the sensitivity of dynamic contrast-enhanced magnetic resonance im-
aging (DCE-MRI), diffusion-weighted (DW)-MRI, in vivo MR spectroscopy (MRS), and ex vivo high-resolution magic
angle spinning (HR MAS) MRS for the detection of early treatment effects after docetaxel administration. Doce-
taxel is an antitumor agent that leads to mitotic arrest, apoptosis, and mitotic catastrophe cell death. Gene expres-
sion analysis was performed to detect altered regulation in gene expression pathways related to docetaxel
treatment effects. Histopathology was used as a measure of alterations in apoptosis and proliferation due to doce-
taxel. Experiments were performed using MCF7 mouse xenografts, randomized into a docetaxel (30 mg/kg) treat-
ment group and a control group given saline. MRI/MRS was performed 1 day before treatment and 1, 3, and 6 days
after treatment. Parametric images of the extracellular extravascular volume fraction (ve) transfer constant (K
trans)
and the apparent diffusion coefficient (ADC) were calculated from the DCE-MRI and DW-MRI data. Biopsies were
analyzed by HR MAS MRS, and histopathology and gene expression profiles were determined (Illumina). A sig-
nificant increase in the ADC 3 and 6 days after treatment and a significant decrease in total choline and a higher
ve were found in treated tumors 6 days after treatment. No significant difference was found in the K
trans between
the two groups. Our results show that docetaxel induces apoptosis and decreases proliferation in MCF7 xeno-
grafts. Further, these phenomena can be monitored by in vivo MRS, DW-MRI, and gene expression.
Translational Oncology (2010) 3, 252–263
Introduction
More than 1 million women worldwide are diagnosed with breast
cancer annually [1]. Recent advances in cancer therapy have aimed
to optimize treatment strategies individually. Docetaxel is used clin-
ically for neoadjuvant treatment of advanced breast carcinomas [2] to
decrease tumor size before surgery and improve the effectiveness of
systemic treatment by fighting micro metastatic disease at an early
stage [2,3]. Clinical assessment of tumor sensitivity to neoadjuvant
chemotherapy is performed within 3 to 4 months (i.e., after three
to four cycles given each 3 weeks) by assessing changes in tumor vol-
ume [4]. Newmethods having the possibility to predict tumor response
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earlier render earlier optimized treatment strategies. This would reduce
health costs and unnecessary adverse effects and increase patient survival.
Docetaxel is a microtubule-stabilizing agent that induces polymeri-
zation of tubulin monomers [5], leading to mitotic arrest in the cell
cycle. Choline (Cho) metabolites have been investigated as biomark-
ers for cell proliferation and tumor metabolism [6–9]. In vivo mag-
netic resonance spectroscopy (MRS) provides quantitative metabolite
information and is thus a promising tool for monitoring changes in-
duced by treatment. By using high-resolution magic angle spinning
(HR MAS) MRS on intact tissue samples, more detailed metabolite
profiles can be obtained. Various studies have revealed an increased
Cho uptake, an upregulated activity of choline kinase and an in-
creased level of phosphocholine (PCho) in cancer cells [10–12]. A
previous study in our laboratory observed decreased choline metabo-
lite levels in docetaxel-treated tumors using in vivo MRS and ex vivo
HR MAS MRS [6].
After mitotic arrest induced by treatment, tumor cells generally en-
ter apoptosis or undergo mitotic catastrophe cell death [13,14]. The
motion of water molecules is restricted by cell membranes and macro-
molecules. Because of this, changes in diffusion-weighted (DW) MRI
may be an effective early biomarker for monitoring docetaxel treat-
ment effects. Successful anticancer therapies have been observed to
cause early increases in the tumor apparent diffusion coefficient
(ADC) in both animals and humans [15–18]. DW-MRI may monitor
docetaxel effects in subtumor areas and differentiate necrotic and viable
tissue [19].
In addition to induced cell death, docetaxel inhibits several endo-
thelial cell functions, impairing the development of essential tumor
vasculature [20]. Dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) is a widely used tool for evaluating tumor vas-
culature. Contrast enhancement in tumor tissue depends on factors
such as tumor vasculature, tissue perfusion, vessel permeability, and
the volume of the extracellular extravascular space. The contrast en-
hancement curves can be analyzed either empirically [21] or with
model-based quantitative methods [6,22]. Several studies have shown
decreased contrast enhancement [21,23,24] and a decreased K trans
[18,25] after successful treatment. Jensen et al. [6] showed a slight
decrease in K trans in MCF7 xenografts due to docetaxel treatment.
When a tumor responds to therapy, a cascade of different incidents
is actuated. The cytostatic effect of docetaxel will affect the tumor
microenvironment, which, in turn, might affect the tumor gene ex-
pression profile. Gene expression analysis gives information about
processes controlled at the messenger RNA level and might therefore
add valuable information for understanding treatment effects de-
tected by MRS, DCE-MRI, and DW-MRI.
Because early treatment monitoring may provide important infor-
mation about patient management, the purpose of this study was to
evaluate DCE-MRI, DW-MRI, in vivo MRS, and ex vivo HR MAS
MRS as tools for detecting early effects of docetaxel treatment. Gene
expression analysis using Illuminamicroarray (Illumina, Inc, SanDiego,
CA) was performed to study the underlying molecular mechanisms.
Proliferation and apoptotic index, determined by histopathology, were
used as measures for docetaxel treatment effects.
Materials and Methods
Mice and Tumors
Human MCF-7 (ATCC-HTB-22; American Type Culture Collec-
tion, Manassas, VA) breast cancer cells were cultured as recommended
by the supplier. Female 6-week-old athymic mice (BalbC/c nu/nu;
Møllergård, Denmark; mean weight, 20 g) were allowed to acclimatize
for 1 week and cared for as previously described [6]. A 17β-estradiol
pellet (0.72 mg, 90 days release; Innovative Research of America, Sara-
sota, FL) was implanted subcutaneously into the neck to facilitate op-
timal tumor growth for the estrogen receptor–positive MCF7 cells.
Three weeks later, xenografts were initiated by subcutaneously inject-
ing MCF7 cells (5 × 106 suspended in 0.5 ml of BD Matrigel Matrix;
BD Biosciences, Bedford, MA) into the flank of the right hind leg.
Two perpendicular tumor diameters (a and b) were measured three
times a week to follow tumor progression. Tumor volumes were cal-
culated as vol = πab2/6, the volume of a prolate ellipsoid, assuming
the third diameter to be equal to the shorter of the two measured.
Seven weeks after implantation, 18 mice with a volume of 207 ±
89 mm3 (mean ± SD) were included in the study and randomized into
two groups (treatment group n = 12, controls n = 6). Seven mice (treat-
ment group n = 4, controls n = 3) were examined by MRI 1 day be-
fore treatment (Figure 1). The day after MRI, mice in the treatment
group were given intraperitoneal (i.p.) injections of 30 mg/kg docetaxel
(Taxotere; Aventis Pharmaceuticals, Degenham, UK; n = 12), whereas
controls were given 15 ml/kg saline (n = 6) i.p. The dose was selected
Figure 1. Seven mice were examined by MRI/MRS 1 day before treatment, 12 mice were treated with intraperitoneal (i.p.) injection of
docetaxel, and 6 mice were given saline. Posttreatment MRI/MRS examinations were performed 1, 3, and 6 days after treatment.
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based on a previous study [6]. The schedule for imaging and biopsy
harvest is illustrated in Figure 1. Mice were killed by cervical disloca-
tion, and biopsies were fixed in formalin (4%, 7 months). At day 6 after
treatment, two additional samples from each tumor were stored in
liquid nitrogen and later used for HR MAS MRS and microarray anal-
ysis, respectively.
Estrogen pellet implantation and xenograft initiation were per-
formed under anesthesia (Haldol-Midazolam-fentanyl-sterile water,
2:3:3:4, 0.15 ml/20-g body weight). During the in vivo MR experi-
ments, the mice were anesthetized with Hypnorm-Dormicum-sterile
water (1:1:2, 0.16 ml/20-g body weight). Respiration rate and tem-
perature were monitored during MRI/MRS. The animal protocol
was approved by The National Animal Research Authority.
In Vivo MRI and MRS Examination
The in vivoMRexaminations were performed on a 7.05-T horizontal
bore magnet (BioSpec; Bruker, Ettlingen, Germany) with a quadrature
surface coil. The MRI protocol included measurement of precontrast
T1 values (T10) using a series of spin-echo images with varying rep-
etition times (RARE [Bruker]: echo time (TE) = 12.5 milliseconds;
repetition time (TR) = 150, 600, 1200, 2500, 7500 milliseconds;
RARE factor of 2; 20 × 20 mm2 field of view [FOV]; 128 × 128 ma-
trix; slice thickness of 0.7 mm) followed by a DCE-MRI series of
200 T1-weighted images with identical geometry and a temporal res-
olution of 4.8 seconds (RARE [Bruker]: TE = 7 milliseconds, TR =
200 milliseconds, and RARE factor of 4). All tumors were imaged
with four axial slices to cover the largest tumor area. A bolus dose
of 0.1 mmol/kg gadodiamide (Gd-DTPA-BMA, diluted 1:10 in sa-
line; Omniscan, GE Healthcare, Norway) was injected intravenously
during 4 seconds at the start of the 10th repetition. After the dynamic
series, anatomic postcontrast images were acquired (FLASH [Bruker]:
TE = 5.4 milliseconds, TR = 350 milliseconds, 20 × 20 mm2 FOV,
128 × 128 matrix, slice thickness of 0.7 mm, and 12 slices). Before
further analysis, the signal-to-noise ratio was improved by averaging
2 × 2 voxels in the dynamic series. Regions of interest (ROIs) envel-
oping the tumor were defined with reference to the high-resolution
postcontrast images. The signal enhancement curve for each averaged
voxel inside the ROI was analyzed to determine the relative signal in-
tensity 1 minute after injection (RSI1 min), the area under the curve
during the first 2 minutes (AUC0-2 min), and time to peak. To en-
sure that the conditions for a two-compartment model were fulfilled,
voxels with an RSI1 min less than 80% 1 minute after injection were ex-
cluded from further analysis [26]. The signal intensity was converted to
contrast agent concentration as previously described [6]. Assuming a
two-compartment model and a population-based biexponential vas-
cular input function [27], ve and K
trans were estimated based on the
model of Tofts [22]. Voxels with K trans <0 and >1 and ve >1 were ex-
cluded because of poor curve fitting. Median K trans, ve, and the mean
value of the upper 10% RSI were estimated [28]. The MR images
were analyzed using in-house software developed in MATLAB (The
MathWorks, Inc, Natick, MA).
DW-MRI data were obtained using diffusion-sensitizing gradients
and echo planar imaging with fat suppression and five different b val-
ues (0, 100, 300, 600, and 1000 sec/mm2) with three orthogonal
gradient directions (x, y, z) (TE = 32 milliseconds, TR = 3000 milli-
seconds, diffusion separation time = 14 milliseconds, diffusion gradi-
ent duration = 7 milliseconds, 20 × 20 mm2 FOV, 128 × 128 matrix,
slice thickness of 2 mm, 2 slices). To improve image quality, an EPI
adjust macro (Bruker PV.4.0) was used to optimize the acquisition
delay correction. ADC maps were calculated based on signal intensity
as a monoexponential function of the b values (Bruker PV.4.0). ROIs
enveloping the tumor were obtained with support from the high-
resolution postcontrast images, and the median ADC values were
determined for each ROI.
In vivo MRS volumes of 3 × 3 × 3 mm3 were located within the
tumors. A cube with sides 3 to 5 mm enveloping the MRS volume was
automatically shimmed. Spectra were recorded by a point resolved
spectroscopy sequence (TE = 20 milliseconds and TR = 3000 milli-
seconds) with outer volume and water suppression. The free induc-
tion decay was acquired in 4000 points during 511 milliseconds
(128 averages). A 4-Hz exponential line broadening was performed
before zeropadding and Fourier transformation into 8000 points.
The spectra were phase-corrected, and chemical shifts were referenced
to the total choline (tCho) peak (3.2 ppm). Baseline offset was cor-
rected by subtracting the mean of the noise (8-9 ppm). Normalization
was performed by dividing by the standard deviation of the noise (8-
9 ppm). The relative concentration of tCho was achieved by integrat-
ing between the two nearest local minima of the peak at 3.2 ppm.
Ex Vivo HR MAS MRS
HRMASMR spectra were obtained using a BrukerAvance DRX600
spectrometer with the gradient aligned with the magic angle axis (Bruker
BioSpin). Tumor biopsies (mean weight ± SD of 14.6 ± 2.3 mg) were
cut on ice to fit the MAS rotor (50 μl, 4-mm diameter), and 40 μl of
buffer (D2O containing 1.37 mM trimethylsilyl-3-propionic acid so-
dium salt d4, formate 10.98 mM) was added. The rotors were weighed
before and after assembly.
Single-pulse–acquired and spin-echo spectra were acquired as pre-
viously described [29]. All spectra were recorded within 55 minutes
(mean ± SD of 41 ± 10 minutes, spin rate of 5 kHz, at 4°C). Spectra
were processed with an exponential filter of 0.3 Hz, and the phase
and baseline offset were corrected. Trimethylsilyl-3-propionic acid
sodium salt d4 served as a chemical shift reference. The peak areas
of glycerophosphocholine (GPC), PCho, Cho, and formate were cal-
culated by peak fitting the pulse-acquired spectra (PeakFit; SeaSolve
Software, Inc, San Jose, CA). The formate peak (corrected for biopsy
weight and added buffer) served as a reference for quantification and
multivariate data analysis.
Histopathologic Examinations
The formalin-fixed and paraffin-embedded biopsies were cut into
4-μm sections and stained with hematoxylin, eosin, and saffron
(HES). Immunohistochemical staining for the proliferation marker
Ki-67 was carried out using MIB1 (monoclonal mouse anti-rat Ki-67
antigen; DakoCytomation, Glostrup, Denmark) and for apoptotic
cells using M30 Cytodeath (Roche Diagnostics GmbH, Penzberg,
Germany) according to the manufacturers’ instructions after antigen
retrieval by pressure cooking. The HES-, MIB1-, and M30-stained sec-
tions were examined microscopically by an experienced pathologist.
The number of mitotic cells was counted in the HES-stained sections
(per 10 FOVs at 400× magnification), and the proliferation index and
apoptotic index were estimated as the number of MIB1- and M30-
positive nuclei, respectively, per 1000 tumor cells.
RNA Isolation and Gene Expression
Total RNA was extracted from control (n = 5) and treated (n = 6)
tumors harvested 6 days after treatment (mean weight ± SD of 53 ±
23 μg) using the Magna Pure LC RNA isolation kit II for tissue
254 Multimodal Monitoring of Early Treatment Effects Huuse et al. Translational Oncology Vol. 3, No. 4, 2010
(Roche). Cells were lysed with 600 ml of lysing buffer, and RNA was
isolated with 350 μl of lysate supernatant in accordance with the manu-
facturer’s protocol. Total RNA amount and quality was examined with
a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies,
Wilmington, DE) and an Agilent 2100 Bioanalyzer RNA 6000 pico
kit (Agilent Technologies, Santa Clara, CA).
Total RNA (300-500 ng) was converted to complementary DNA
using the Illumina TotalPrep RNA Amplification Kit. Complemen-
tary DNA (750 ng) was hybridized to a human Ref-8 BeadChip Array
(Illumina, Inc) following the Illumina Whole-Genome Gene Expres-
sion Protocol for BeadStation; gene expression analysis was performed
using the Sentrix BeadChip and BeadStation system from Illumina.
Data were log2-transformed and quantile-normalized using R (version
2.6.1; The R Foundation for Statistical Computing http://www.gnu.
org/licenses/gpl.html). Significantly differentially expressed genes were
identified using a modified t test [30], correcting for multiple testing
using the method of Benjamini and Hochberg [31] to arrive at false
discovery rate P values.
The gene data set was exported for gene set enrichment analysis
(GSEA, Broad Institute of MIT and Harvard, MA) [32]. The Kyoto
Figure 2. (A and C) Box plots of median ve and K
trans values for control and treated tumors 1 day before (pre) treatment and 1, 3, and
6 days after (post) treatment. (B and D) ve and K
trans maps from about the same region in a treated tumor 1 day before treatment and
3 and 6 days after treatment. ○ indicates observations of 1.5 interquartile ranges from the end of the box; #, significant difference (t test)
between treated and control on the same day.
Figure 3. (A) Box plot showing progress in the median ADC 1 day before (pre) treatment and 1, 3, and 6 days after (post) treatment.
Asterisk (*) indicates significant difference (Dunnet) between before and after treatment; #, significant difference (t test) between treated
and control on the same day. (B and C) ADC maps from a control tumor and a treated tumor 1 day before (pre) treatment and 3 days after
(post) treatment.
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Encyclopedia of Genes and Genomes [33–35] was used to define
the a priori gene sets. In addition, a gene set was manually created
by including genes involved in PCho metabolism described by Eliyahu
et al. [36]: choline high-affinity transporter 1 (SLC5A7), organic cat-
ion transporter 1 (SLC22A1), organic transporter 2 (SLC22A2), choline
transport-like protein 1 (CTL1), phospholipase D (PLD), choline ki-
nase α (CHKA), and choline kinase β (CHKB). For the GSEA, P <
.05 and false discovery rate <.25 were considered significant.
Statistical and Multivariate Analysis
Statistical analyses were performed using SPSS 15.0 (SPSS, Inc,
Chicago, IL). Independent-sample t test was used to compare the con-
trol group to the treatment group on each day after treatment, and
one-way analysis of variance test (Dunnet) was used to compare post-
treatment and pretreatment parameters in each group. Unequal var-
iances were assumed. Outliers were identified using the extreme
studentized deviate procedure with 95% confidence interval, assuming
normal distribution verified visually by a Q-Q plot.
Pearson correlation coefficients between the histopathologic param-
eters (number of mitoses, proliferation index, and apoptotic index) and
the in vivo MR parameters (median K trans, median ve, median ADC,
and tCho) were calculated.
The relationship between HR MAS MR spectra (spectral region
0.5-4.7 ppm) and histopathologic parameters was investigated by par-
tial least squares (PLS) regression using The Unscrambler (CAMO
Software AS, Oslo, Norway). In PLS, principal components (PCs)
are derived to maximize the covariance between the spectra (X ) and
class-assigned target values (Y ). For proliferation index and number
of mitoses as target values, the spin-echo spectra were used as input,
whereas pulse-acquired spectra were used for the apoptotic index. PLS
was carried out using full cross-validation and mean centering, and the
number of PCs retained was determined by the PC, minimizing the
error of prediction. Score plots and loading profiles were examined.
Results
In Vivo MRI and MRS Examinations
There were no significant changes in tumor growth based on outer
tumor volume measurements during the 6-day posttreatment period.
Figure 4. (A) In vivo tCho levels showing a significant difference between treated and control tumors 6 days after treatment. (B) Mean
in vivo MR spectra from the two groups showing a shift in parts per million (ppm) values for the fatty acids and a decrease in tCho after
docetaxel treatment. (C) Metabolite concentrations estimated from ex vivo HR MAS MR spectra relative to formate. There was a trend
for the concentration of all choline-containing metabolites to decrease. (D) Mean HR MAS MR spectra of treated and control tumors
6 days after treatment. The treated tumors have a higher content of –(CH2)n and –CH3 fatty acids. X indicates a single tumor excluded
from the statistical analysis; #, significant difference (t test) between the two groups.
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Figure 2 summarizes the results from the DCE modeling. The prog-
ress during the week of follow-up indicated a trend of decreasing ve
in the control tumors, with the largest difference compared with the
treated tumors 6 days after treatment (P = .053). No differences were
found in K trans before and after treatment or between the two groups
for the semiquantitative parameters AUC, time to peak, and RSI.
One tumor examined before treatment was excluded from the analysis
because the volume (86 mm3) was too small to obtain in vivo MRS or
precise ROIs. Three DCE measurements were excluded because of
unsuccessful contrast injection (a treated tumor 3 days after treatment,
a control tumor, and a treated tumor 6 days after treatment).
Treated tumors had a significantly increased median ADC 3 and
6 days after treatment compared with before treatment (P < .005 and
P < .001, respectively; Figure 3A). There were no changes in the con-
trol tumors during the follow-up. A significant difference was ob-
served between the two groups 3 and 6 days after treatment (P <
.0005 and P < .05, respectively). ADC maps of a control tumor and
treated tumor before and 3 days after treatment are shown in Figure 3,
B and C . The DW-MRI from a control tumor 1 day after treatment
was excluded because of severe ghosting artifacts. In addition, the ADC
values from a control tumor at days 3 and 6 after treatment were iden-
tified as outliers (extremely high ADC values, P < .01).
Treated tumors showed a drop in tCho levels measured by in vivo
MRS 3 days after treatment and a slight increase from 3 to 6 days
after treatment (Figure 4A). By comparing tCho levels in the two
groups, the largest change was found during the day 1 to day 3 post-
treatment period (mean decrease of 38%), but a significant difference
in tCho was only observed between the treated and control tumors at
day 6 after treatment (P < .05, t test). One tumor was excluded from
the statistical analysis because of a very high initial level of tCho.
However, this tumor followed the same trend as the others.
Ex Vivo HR MAS MRS
The HR MAS MR pulse-acquired spectra indicated a lower, al-
though not significant, GPC, PCho, and Cho level in the treated
Figure 5. Histopathology 6 days after treatment of control (n = 4) and treated tumors (n = 7). (A) HES-stained section with apoptotic (A)
and mitotic (M) cells. A trend of higher number of mitoses was detected in control tumors than in treated (P = .065) was detected. (B)
Nuclear staining with Ki-67 MIB1 showing extensive proliferative activity. The control tumors had significantly higher proliferation than
the treated (P= .024). (C) M30 cytodeath–stained section showing positive staining in the cytoplasm of an apoptotic cell. Control tumors
had a significantly lower apoptotic index than the treated (P < .01). #Significant difference (t test) between the two groups. ○ indicates
observations of 1.5 interquartile ranges from the end of the box.
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tumors (Figure 4C ). A higher –(CH2)n and –CH3 fatty acid content
were also observed (Figure 4D).
Histopathologic Examinations
The histopathologic results are summarized in Figure 5. The pro-
liferation index 6 days after treatment was significantly lower (P <
.05) in the treated tumors (mean ± SD of 458 ± 95 MIB1-stained
cells per 1000 cells) compared with controls (mean ± SD of 592 ±
66). In addition, treated tumors had a trend of lower number of mi-
totic cells (mean ± SD of 21.6 ± 16.7 per 10 × 400 fields) than the
controls (mean ± SD of 36.0 ± 4.2, P = .065). Furthermore, the treated
tumors had a significantly higher (P < .01) apoptotic index (mean ±
SD of 88.9 ± 53.0 stained cells per 1000 cells) compared with con-
trols (mean ± SD of 15.3 ± 11.9).
Correlation between MR Extracted Parameters
and Histopathology
There were significant correlations between the median ve and the
number of mitoses (r = −0.632, P < .05) and the proliferation index
(r = −0.601, P < .05) and the apoptotic index (r = 0.674, P < .05).
K trans, ADC, and tCho were not correlated with any of the histo-
pathologic parameters.
A PLS model relating spectra and mitotic cells (five PCs) explained
94% and 100% of the X and Y variance, respectively. The ex vivo HR
MASMRS–predicted versus histologically measured number of mitotic
cells was significantly correlated (calibration r = 0.999/validation r =
0.935, P < .001; Figure 6A). Tumors characterized by a high num-
ber of mitoses had a high score for PC1, and the corresponding load-
ing profile showed higher concentrations of GPC, PCho, creatine, and
taurine (Figure 6, B and C). A PLS model relating spectra and apop-
totic index (4 PCs) explained 98% and 97% of the X and Y variance,
respectively. The ex vivoHRMAS MRS–predicted versus histologically
measured apoptotic index was significantly correlated (calibration r =
0.946/validation r = 0.680, P < .05; Figure 7A). Tumors characterized
by a high apoptotic index had a high score for PC1, and the corre-
sponding loading profile showed higher concentrations of –(CH2)n
and –CH3 fatty acids (Figure 7, B and C ). A PLS model relating spec-
tra to the proliferation index (four PCs) explained 94% and 97% of
the X and Y variance, respectively. There was a correlation between
the ex vivo HR MAS MRS–predicted and the measured proliferation
index (calibration r = 0.978/validation r = 0.651, P = .058; Figure 8A).
Figure 6. Results from the PLS regression analysis of HR MAS MR spin-echo spectra (spectral region 0.5-4.7 ppm) and the number of
mitoses. (A) The predicted versus the measured number of mitoses for the calibration (red) and validation (blue). The Pearson correlation
coefficients for the calibration (rcal), validation (rval), and the P value for the validation are marked. The total residual variance and root
mean square error of prediction were minimized by retaining five PCs in the model. These five PCs accounted for 94% of the total X
variation and 100% of the total Y variation. (B) Score plot of the PC1 versus PC2 from the PLS analysis. (C) The corresponding loading
profile of PC1 illustrates that tumors with many mitoses have higher concentrations of GPC, PCho, creatine, and taurine. The following
metabolites are assigned in the loading profile (peak number in parentheses): (1, 2) fatty acids, (3) lactate, (4) alanine, (5, 12) creatine,
(6) choline, (7) PCho, (8) GPC, (9, 10) taurine, and (11) glycine. In panels A and B, • control tumors and ▴ treated tumors.
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Tumors with a high proliferation index had a higher score for PC1
and were dominated by higher concentrations of GPC, PCho, and
taurine (Figure 8, B and C). One tumor was defined as an outlier by
the extreme studentized deviate procedure and was excluded.
Gene Expression Analysis
Among the 22,000 genes investigated, 107 were found to be sig-
nificantly different between the control and treated tumors. Among
these genes, 56 were downregulated and 51 were upregulated. Table 1
lists the genes of interest for docetaxel treatment based on literature
describing processes such as angiogenesis, apoptosis, cell cycle, prolif-
eration, microtubule reorganization, and tumor metabolism related to
treatment response. The results of the GSEA did not provide any gene
sets that were significantly enriched. Gene expression data were cor-
related to metabolite levels on the same samples using PLS. Cross-
validation revealed no predictive ability (q2 = 0.11), and testing of
individual genes using moderated Hotelling T 2 statistic found no sig-
nificant individual genes [37]. Two samples with an RNA integrity
number lower than 6 were excluded from the analysis (treated tumors).
Discussion
The methods used in this study showed increased diffusion, altered
metabolic and gene expression profiles, increased apoptosis, and de-
creased proliferation in a human breast cancer model treated with
docetaxel, despite no significant change in tumor volume. The doce-
taxel treatment effects on the tumor microenvironment detected by
DW-MRI were greatest 3 days after treatment and tended to fade out
6 days after treatment. No significant change in tumor volume indi-
cates that a single i.p. dose of 30 mg/kg docetaxel initiates only minor
treatment effects. Jensen et al. found significant differences in growth
after docetaxel treatment. The tumors included in that study were
larger than those used here, and thus, the lack of change in tumor
volume differences here might be due to a higher relative measure-
ment uncertainty. However, histopathology verified a docetaxel effect
observed as a significantly lower proliferation index and higher apop-
totic index after treatment.
A decreased ve in controls corresponds to a decreased space avail-
able for the contrast agent, which is in accordance with the high pro-
liferation seen in controls. The negative correlation between the ve
Figure 7. Results from the PLS regression analysis of HR MAS MR pulse-acquired spectra (spectral region 0.5-4.7 ppm) and the apop-
totic index. (A) The predicted versus the measured apoptotic index for the calibration (red) and validation (blue). The Pearson correlation
coefficients for the calibration (rcal), validation (rval), and the P value for the validation are marked. Total residual variance and root mean
square error of prediction were minimized by retaining four PCs in the model. These four PCs accounted for 98% of the total X variation
and 97% of the total Y variation. (B) Score plot of the PC1 versus PC2 from the PLS analysis. (C) The corresponding loading profile of PC1
illustrates that tumors with a high apoptotic index have higher concentrations of –(CH2)n and –CH3 fatty acids. The metabolites that are
assigned with numbers are listed in the legend of Figure 6. In panels A and B, • control tumors and ▴ treated tumors.
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and the number of mitoses and also the proliferation index, together
with the positive correlation between the ve and apoptosis, confirms
that the ve is related to changes in the tumor microenvironment. The
lack of difference in K trans between the two groups indicates the lim-
ited changes in the tumor vasculature. Other studies have shown that
docetaxel has antiangiogenic effects [20,38] causing decreased K trans
in tumors [25,39]. However, changes in tumor vasculature caused by
a single i.p. injection may be too small to be detected by current meth-
odologies. Jensen et al. found a trend to increase in both ve and K
trans
after treatment, given a higher dose of docetaxel (40 mg/kg) [6]. Gado-
diamide, a small molecule contrast agent, was chosen because it is
widely used in the clinic. A contrast agent with a higher molecular
weight would change the conditions for the model [22], improving
the sensitivity for changes in K trans.
The increased median ADC values of the treated tumors 3 and
6 days after treatment are consistent with the increased tissue water
mobility, which can be caused by a loss of cell volume, breakdown of
the plasma membrane, or cell death [15], confirmed by the decreased
proliferation index and increased apoptotic index found by histo-
pathology. However, there was no significant correlation between
the ADC and any histopathologic parameter, indicating that the ab-
solute value of the ADC is influenced by more than increased apop-
tosis and decreased proliferation. The increase in the ADC shortly
after treatment is in accordance with previous findings [15,40] and
supports DW-MRI as a suitable method for monitoring early doce-
taxel treatment effects.
The in vivo tCho signal depends on the cellular concentration of
GPC, PCho, and Cho. GPC is a membrane breakdown product,
whereas PCho is also a precursor of the membrane component phos-
phatidylcholine. Decreased tCho levels after docetaxel treatment is in
accordance with earlier findings [6] and supports the hypothesis that
MRS can observe changes in metabolism. The decreased tCho could
also be due to less cell density, which is in agreement with histo-
pathology and the increase in the ve and ADC after treatment.
Figure 8. Results from the PLS regression analysis of HR MAS MR spin-echo spectra (spectral region 0.5-4.7 ppm) and the proliferation
index. (A) The predicted versus measured the proliferation index for the calibration (red) and validation (blue). The Pearson correlation
coefficients for the calibration (rcal), validation (rval), and the P value for the validation are marked. Total residual variance and root mean
square error of prediction were minimized by retaining four PCs in the model. These four PCs accounted for 84% of the total X variation
and 96% of the total Y variation. (B) Score plot of the PC1 versus PC2 from the PLS analysis. (C) The corresponding loading profile of PC1
illustrates that tumors with a high proliferation index have a higher concentration of GPC, PCho, and taurine. The metabolites that are
assigned with numbers are listed in the legend of Figure 6. In panels A and B, • control tumors and ▴ treated tumors.
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The decrease in PCho and Cho after treatment is in accordance
with earlier findings [9,41]; however, these studies reported increased
GPC after treatment. Consistent with our findings, Jensen et al. [6]
reported decreased GPC in docetaxel-treated MCF7 xenografts. The
absence of significant changes in GPC, PCho, and Cho levels in the
ex vivo tissues could be due to late biopsy harvest (6 days after treat-
ment) or due to tumor heterogeneity. The PLS score values and
corresponding loading profiles substantiate that highly proliferative
tumors with many mitoses have a higher concentration of GPC,
PCho, and Cho. It has been previously observed that PCho and
Cho levels increase with tumor malignancy [7,36] because of the
stimulation of choline transport caused by the up-regulation of cho-
line transporters encoded by SLC5A7 and SLC22A2 and choline
phosphorylation caused by the enzyme choline kinase alpha [36] en-
coded by CHKA. No such differences in gene expression between the
two groups were found to explain the differences in choline metab-
olism in our study. Our results are in accordance with an in vitro
study of docetaxel-treated MCF7 cells using polymerase chain reac-
tion [12]. Taken together, these findings suggest that the decreased
level of GPC, PCho, and Cho after docetaxel treatment might be
caused by a mechanism other than the regulation of genes involved
in the glycerophospholipid metabolic pathway.
Consistent with the histopathology, the expression levels of genes
involved in the cell cycle and proliferation indicate decreased prolif-
eration in treated tumors. Interactions between the Golgi and micro-
tubules are important for the postfragmentation reorganization of the
Golgi during mitosis. The expression of GOLGA3, GOLGB1, and
KIF4A indicates decreased movement along the microtubules, which
also agrees with the expected docetaxel treatment effects [5].
Tumors with high apoptotic activity had a higher content of –(CH2)n
and –CH3 fatty acids. Mean ex vivo HR MAS MR spectra and PLS
analysis relating apoptotic index to the spectra showed a clear differ-
ence in lipid content. Lipase gastric (LIPF ), which is involved in glycero-
lipid metabolism [42] and hydrolyzes the ester bonds of triglycerides
into fatty acids, was found to be significantly upregulated in treated
cells. This finding might explain the elevated levels of –(CH2)n and
–CH3 fatty acids in the docetaxel-treated tumors and may be related
to the elevated apoptotic index. Previous studies in glioma models
have shown increased lipid content to be a function of a high apopto-
tic cell fraction [43]. Also, HR MAS MRS of human cervical cancer
specimens has revealed similar correlations [44].
Four genes known to be involved in apoptosis were found to be
differentially expressed between the two groups, and their up- and
down-regulation indicate increased apoptotic activity after treatment
(Table 1), which is in agreement with the histopathology. TNFSF10
and CASP6, together with tumor necrosis factor receptor superfamily
member 10b (TNFRSF10B, P = .088), were located along the caspase-
mediated apoptotic pathway. Thus, three of six genes along the same
Table 1. A Selection of Differentially Expressed Genes Related to Cancer and Docetaxel Treatment Response.
Gene Full Name Description Up/Down P Gene ID and
Additional References
TNFSF10 Tumor necrosis factor receptor superfamily
member 10
Also known as TRIAL, protein inducing apoptosis in tumor cells. Up .04 8743 [50]
CASP6 Caspase 6 apoptosis-related cysteine peptidase Involved in late apoptosis. Up .02 839 [51,52]
CARD8 Caspase recruitment domain family member 8 Encodes an adaptor molecule that suppresses apoptosis. Down .04 22900 [53]
GAS2L1 Growth arrest-specific 2 like 1 Encodes an actin-associated protein expressed at high levels in
growth-arrested cells.
Down .01 10634 [45,46,54,55]
CDC45L Cell division cycle 45-like Encodes a proliferation-associated protein (Cdc45) present in proliferating
cells and plays a critical role in DNA replication by ensuring that
chromosomal DNA is replicated only once per cell cycle.
Down .02 8318 [56,57]
GOLGA3 Golgi autoantigen, golgin subfamily a3 Encodes the protein golgin-160, which is important for interactions between
the Golgi and microtubules and thought to be important for reorganization
of the Golgi during mitosis. Cleavage of golgin-160 also plays an important
part in events leading to apoptosis.
Down .04 2802 [58,59]
KIF4A Kinesin family member 4A Encodes a microtubule-based motor protein that generates directional movement
along microtubules.
Down .03 24137 [60]
GOLGB1 Golgin B1, golgi integral membrane protein Encodes the protein giatin, which is involved in Golgi structure and trafficking. Up .04 2804 [61]
GBP2 Guanylate binding protein 2 GBP2 is the main transcriptional activator of the interferon encoded by IFR1.
Interferons are cytokines that inhibit tumor cell proliferation.
Up .00 2634 [61,62]
GHRL Ghrelin/obestatin prepropeptide Encodes the protein obestatin, which is involved many processes affecting
cell proliferation.
Up .03 51738 [63,64]
INTS6 Integrator complex subunit 6 A candidate tumor suppressor gene. Down .04 26512 [65,66]
TAOK2 TAO kinase 2 Has a role in cell signaling, microtubule organization and stability, and apoptosis. Down .03 9344
RPS6KA1 Ribosomal protein S6 kinase, 90 kDa,
polypeptide 1
Implicated in controlling cell growth and differentiation. Down .04 6195
RPS6KA5 Ribosomal protein S6 kinase, 90 kDa,
polypeptide 5
Involved in signal transduction and located in the MAPK signaling pathways.
Related to cancer.
Up .02 9252
EVI1 Ecotropic viral integration site 1 Increased copy number and transcript levels are associated with improved
patient outcomes.
Up .03 2122 [67]
SUFU Suppressor of fused homolog Associated with cancer-predisposing syndromes. Down .01 51684
PIAS4 Protein inhibitor of activated STAT, 4 Involved in signal transduction and related to cancer. Down .03 515888
DDR1 Discoidin domain receptor tyrosine kinase 1 Encodes a receptor tyrosine kinase (RTK) involved in regulation of cell growth,
differentiation, and metabolism. RTKs are important for communication
between cells and their microenvironment.
Down .05 780
LIPF Lipase, gastric Encodes gastric lipase, which hydrolyzes the ester bonds of triglycerides under
acidic pH conditions.
Up .02 8513 [42]
ACLY ATP citrate lyase Involved in metabolism. Down .02 47
BTN2A2 Butyrophilin, subfamily 2, member A2 Encodes a type 1 receptor glycoprotein involved in lipid, fatty acid and
sterol metabolism.
Up .01 10385
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apoptotic pathway were upregulated. In addition, GAS2L was found
to be significantly downregulated. This gene encodes growth arrest–
specific protein 2 (Gas2), which colocalizes with actin at the cell border
and along stress fibers in growth-arrested cells. GAS2L1 is highly up-
regulated in growth-arrested cells in vitro; however, it becomes down-
regulatedwhen arrested cells reenter the cell cycle [45,46]. This indicates
that the mitotic arrest caused by docetaxel is about to be almost elim-
inated 6 days after treatment, which is in accordance with the up-
regulation of late apoptosis-related CASP6. This may also explain why
other genes related to growth arrest, for instance major protein kinase C
substrate (MARCKS) [47], were not significantly changed.
Increased apoptosis 6 days after treatment was confirmed with HR
MAS MRS, gene expression, and immunohistochemistry. However, a
study of MCF7 xenografts by Morse et al. [48] found no apoptotic
activity after docetaxel treatment. They analyzed biopsies grown in
the mammary fat pad, 2 days after treatment, in contrast to the sub-
cutaneous model used in the present study. In addition, the MCF7
cell lines used in the two studies were obtained from different labo-
ratories; thus, the tumors may have different biologic properties [49].
Furthermore, in vitro cell studies from Hernandez-Vargas et al. [13]
showed dose dependency in the mechanism of cell death after doce-
taxel treatment. Low doses (4 nM) induced mitotic catastrophe fol-
lowed by necrosis, and high doses (100 nM) induced apoptosis.
Docetaxel has been found to have antiangiogenic effects [20,38].
In our study, no genes in the vascular endothelial growth factor path-
way as listed in the Kyoto Encyclopedia of Genes and Genomes [33–
35] were found to be significantly different between the two groups.
These data are in agreement with K trans values, which exhibited no
change. Thus, our study suggests limited antiangiogenic effects in tu-
mors after a single docetaxel treatment.
Conclusions
This study shows that in vivo MRS, DW-MRI, and ex vivo HR MAS
MRS are suitable for monitoring early docetaxel treatment effects,
which is promising for translation into the clinic. The histopathologic
results show that an i.p. dose of 30 mg/kg of docetaxel induced apop-
tosis and decreased proliferation in MCF7 xenografts. Of the three
time points chosen for MRI/MRS examination, 3 days after treatment
seems to be most suitable for detecting docetaxel treatment effects and
the effects fade 6 days after treatment. The gene expression analysis
yields a better understanding of the results found by the multimodal
imaging methods.
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